Sandoz seen rising after it secures Canada approval for generic GLP-1 shot
18/09/2026 07:42
BUZZ-Sandoz seen rising after it secures Canada approval for generic GLP-1 shot ** Shares in Sandoz SDZ.S are indicated to rise 3% pre-market after Swiss generic drugmaker received regulatory approval for its generic semaglutide to treat type-2 diabetes in Canada
** The injection is a generic version of Novo Nordisk's NOVOb.CO GLP-1 drug Ozempic, Sandoz says
** The approval does not affect Sandoz's 2026 financial guidance, and it expects no material contribution this year from any potential launches of the drug
** Canadian GLP-1 market is worth $2.6 billion, with close to 12 million semaglutide injection pens issued annually, the company says
(Reporting by Amir Orusov)
Recent news on Novo Nordisk A/S
See all newsFocus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Factbox: Anthropic's public benefit fund and how it compares with other big philanthropic efforts
Novo's CagriSema helped women lose 25% of weight on average, analysis shows
As weight-loss drug users turn to dietary supplements, doctors, regulators raise flags
Factbox: Major drugmakers turn to China for licensing deals